The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

The FDA granted fast track designation for rezpegaldesleukin for treating adults and children aged 12 years and older, ...

Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a ...

AbbVie on Wednesday said the Phase 3 study evaluating the safety and efficacy of Rinvoq in adults and adolescents with severe alopecia areata met its primary endpoint of 80% or more scalp hair ...

Alopecia areata (AA) has a severe psychosocial impact, which is linked to illness perceptions and stigma more strongly than ...

Alopecia areata is an autoimmune disease responsible for hair loss. While it has no cure, understanding the triggers and avoiding certain things can help manage the condition better.

Rezpegaldesleukin targets the interleukin-2 receptor complex in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells.

Nektar Therapeutics ( NASDAQ: NKTR) has announced that the FDA has awarded Fast Track designation to its experimental drug rezpegaldesleukin, a treatment for severe-to-very severe alopecia areata.

Alopecia areata, an autoimmune disorder causing hair loss, now has an FDA-approved treatment since June 2022. While some explore home remedies like essential oils, dietary changes, and stress ...

Panelists discuss how the epidemiology of alopecia areata (AA) varies across different patient populations, with certain forms of the disease being more prevalent in specific groups.

A bbVie has reported encouraging topline outcomes from the first of two replicate trials of the Phase III UP-AA programme, ...

Alopecia areata is a complex autoimmune condition, where a person’s immune system mistakes their hair follicles as a foreign body and attacks them.